{"id":1786196,"date":"2022-12-25T06:30:07","date_gmt":"2022-12-25T11:30:07","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=1786196"},"modified":"2022-12-25T08:18:39","modified_gmt":"2022-12-25T13:18:39","slug":"is-the-white-houses-push-for-paxlovid-evidence-based","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/is-the-white-houses-push-for-paxlovid-evidence-based\/","title":{"rendered":"Is the White House\u2019s Push for Paxlovid Evidence-Based?"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">16<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fis-the-white-houses-push-for-paxlovid-evidence-based%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=1786196&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><p>The Biden administration and government agencies continue to <a href=\"https:\/\/www.whitehouse.gov\/briefing-room\/press-briefings\/2022\/04\/26\/press-briefing-by-press-secretary-jen-psaki-and-white-house-covid-19-response-coordinator-dr-ashish-jha\/\">push<\/a> Pfizer\u2019s COVID-19 emergency use authorization product, <a href=\"https:\/\/www.paxlovid.com\/faq\">Paxlovid<\/a>, even with\u00a0insufficient new trial data showing effectiveness in the current population.<\/p>\n<p>Pfizer\u2019s <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2118542\">initial clinical trial<\/a> for <a href=\"https:\/\/www.theepochtimes.com\/t-paxlovid\">Paxlovid<\/a> in 2021, which earned it an\u00a0<a href=\"https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#coviddrugs\">emergency use authorization<\/a>\u00a0(EAU) by the FDA, seemed quite promising. Results showed a relative risk reduction of progression to severe COVID-19 at 89 percent. But after the unapproved Pfizer product hit the market with its EAU in tow, <a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac443\/6599020?login=false\">real-world studies<\/a> came out quite differently.<\/p>\n<p>Two studies between January and March 2022, using real-population-based data, showed many different results. In the first <a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac443\/6599020\">study<\/a> published in Clinical Infectious Diseases in June 2022, the risk reduction was much smaller than in the initial 2021 trial (89 percent), coming in at 46 percent.\u00a0 Results from the second<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2204919\"> study,<\/a>\u00a0published in The New England Journal of Medicine in September, showed no evidence of avoidance of severe COVID-19 in adults younger than 65.<\/p>\n<p>The EUA and push for use of Paxlovid continue despite falling efficacy rates, and the FDA hasn\u2019t yet ordered Pfizer to produce a new randomized double-blind control clinical trial to confirm its efficacy in the current real-world population.<\/p>\n<p>The Food and Drug Administration (FDA) has instead\u00a0<a href=\"https:\/\/www.fda.gov\/media\/155049\/download\">ordered<\/a> Pfizer to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound of COVID-19 after treatment. When splashed across headlines that three high profile government officials, <a href=\"https:\/\/www.theepochtimes.com\/biden-still-positive-for-covid-19-as-he-deals-with-pfizer-drug-rebound-doctor_4635382.html\">President Joe Biden<\/a>,<a href=\"https:\/\/www.theepochtimes.com\/fauci-reveals-covid-19-rebound-after-taking-pfizers-paxlovid-drug_4566468.html\"> White House <\/a><a href=\"https:\/\/www.theepochtimes.com\/t-covid-19\">COVID-19<\/a><a href=\"https:\/\/www.theepochtimes.com\/fauci-reveals-covid-19-rebound-after-taking-pfizers-paxlovid-drug_4566468.html\"> adviser Dr.\u00a0<\/a><a href=\"https:\/\/www.theepochtimes.com\/t-anthony-fauci\">Anthony <\/a><a href=\"https:\/\/www.theepochtimes.com\/fauci-reveals-covid-19-rebound-after-taking-pfizers-paxlovid-drug_4566468.html\">Fauci<\/a>, and most recently\u00a0<a href=\"https:\/\/www.theepochtimes.com\/health\/cdc-director-issues-alert-on-pfizers-covid-19-pill-you-might-get-symptoms-again_4503262.html\">Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky<\/a>, all reported <a href=\"https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp\">COVID rebound<\/a> after taking Pfizer\u2019s Paxlovid, marking a negative turn of events for the Pfizer drug.<\/p>\n<p>But with treatment courses of Paxlovid at $530, and the U.S. government\u2019s <a href=\"https:\/\/www.theepochtimes.com\/us-to-pay-pfizer-2-billion-for-3-7-million-more-courses-of-paxlovid_4922710.html\">announcement<\/a> on Dec. 13 of a new purchase of 3.7 million courses for around $2 billion in addition to its <a href=\"https:\/\/www.theepochtimes.com\/fda-authorizes-pfizers-covid-19-pill-after-securing-5-billion-deal-with-federal-government_4172758.html\">previous<\/a> $5 billion purchase of 20 million courses of Paxlovid earlier this year,\u00a0 the drug remains quite profitable for Pfizer.<\/p>\n<p>So what are the facts about Paxlovid we need to know?<\/p>\n<h2><b>What Is Paxlovid?<\/b><\/h2>\n<p>Paxlovid consists of two active drugs, nirmatrelvir and ritonavir. Nirmatrelvir is designed to inhibit viral replication and ritonavir is a protease inhibitor that was used for the treatment of HIV\/AIDS.<\/p>\n<p>Paxlovid is currently not approved by the FDA for any use, including for treatment of COVID-19, and is still being studied. Late in December 2021, the investigational medicine was granted emergency use authorization (EUA) in the U.S. by the FDA as a therapy to treat mild-to-moderate COVID-19 in adults and children 12 and older weighing at least 88 lb.<\/p>\n<p>Currently, the safety and efficacy of Paxlovid in <a href=\"https:\/\/www.fda.gov\/media\/155050\/download\">pediatric patients<\/a> younger than 18 hasn\u2019t been established and no data is available as clinical trials to date included adults 18 and older. Pfizer does mention that the authorized adult dosage is expected to result in a comparable outcome in patients 12 years of age and older weighing at least 88 pounds as observed in adults with similar body weight in the trials.<\/p>\n<h2><b>Efficacy Rates<\/b><\/h2>\n<p>The data supporting the EUA was based on Paxlovid\u2019s first clinical trial between July 16 and December 9, 2021, showing an 89 percent reduction in severe COVID-19 outcomes. This <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04960202\">initial clinical trial<\/a> was done on a very select group. Participants were symptomatic and COVID-positive, had at least one underlying medical condition with an increased risk of developing severe illness from COVID-19, and had no previous confirmed SARS-CoV-2 infection.<\/p>\n<p>The first <a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac443\/6599020?login=false\">study<\/a> from Israel, done between January and February using real population-based data was based on a more diverse group. 78 percent of participants had previous COVID-19 immunity from a prior SARS-CoV-2 infection, or were vaccinated, and estimated to be at high risk for progression to severe COVID-19.\u00a0 The outcome showed an overall risk reduction of 46 percent. It\u2019s noted in the study that because Paxlovid isn\u2019t recommended for use with several medical conditions and has complex drug-drug interactions, it may limit the drug\u2019s use in high-risk patients.<\/p>\n<p>The second <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2204919\">study<\/a> using real population-based data done between January and March 2022, tested results based on two age groups, 40-64 and 65 years of age or older. Results showed rates of severe COVID-19 outcomes were significantly lower in adults 65 years of age and older who received Paxlovid but there was no evidence of benefit found in adults under 65.<\/p>\n<p>Currently, the <a href=\"https:\/\/www.fda.gov\/media\/155051\/download\">FDA<\/a>, the <a href=\"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/treatments-for-severe-illness.html\">CDC<\/a>, and <a href=\"https:\/\/www.paxlovid.com\/\">Pfizer<\/a> all maintain broad treatment guidelines for Paxlovid, stating it\u2019s for adults and children over 12, weighing at least 88 lbs.<\/p>\n<p>Pfizer\u2019s most recent <a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study\">clinical trial<\/a> reported in late April determined post-exposure prophylactic use. Eligible participants were again a very specific group; asymptomatic, had a negative screening SARS-CoV-2 antigen test result, exposed to a positive symptomatic individual, had not been infected with SARS-CoV-2 in the past 6 months, and had not received any SARS-CoV-2 vaccine within 6 months. Results were reported as not statistically significant, with the endpoint not met. Pfizer reported observed risk reductions of 32 percent (5-day course) and 37 percent reduction (10-day course).<\/p>\n<p>So why in a matter of months, has Pfizer\u2019s new \u201cmiraculous\u201d medication, seemed to lose its staying power? What about new variants you may ask?<\/p>\n<p>\u201cPaxlovid is expected to be active against the Omicron variant and its sub-variants, although there is currently a lack of data on the clinical efficacy of Paxlovid against these variants,\u201d the <a href=\"https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir--paxlovid-\/\">National Institutes of Health (NIH<\/a>) states, while Pfizer also <a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment\">says<\/a> the drug works against Omicron and backs up its claim with three laboratory-based studies.<\/p>\n<p>Setting aside the evolving variants, there is currently no data to tell if Paxlovid is effective on the current population and to what degree it\u2019s working with ever-evolving exposure and immunity. All clinical trials completed to date have had very select criteria. Having more clarity around the current murkiness of this drug sooner than later would be helpful for all, as since mid-April prescriptions for Paxlovid have surged to more than 160,000 per week, according to the <a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7125e1.htm\">CDC<\/a>.<\/p>\n<h2><b>Side Effects and Contraindications<\/b><\/h2>\n<p>As with all pharmaceuticals, Paxlovid has <a href=\"https:\/\/www.fda.gov\/media\/155050\/download\">potential side effects<\/a>. Allergic reactions, hypersensitivity reactions, and anaphylaxis have been reported along with liver problems and a list of others. Dysgeusia, a taste disorder causing a sour, bitter, or metallic taste has also been reported. More recently cases of toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported with ritonavir, a component of Paxlovid. Pfizer does warn that Paxlovid is still being studied, not many people have taken it, and it\u2019s possible that all risks aren\u2019t known at this time.<\/p>\n<p>There is currently no human data on the use of Paxlovid during pregnancy and becoming pregnant during treatment is not currently recommended. It\u2019s reported that it also may affect how birth control pills work.<\/p>\n<p>Currently, the FDA lists 35 <a href=\"https:\/\/www.fda.gov\/media\/158165\/download\">contraindicated drugs<\/a> and herbal products, including anti-cancer drugs and St. John\u2019s Wort that may cause serious or life-threatening side effects when taken with Paxlovid, as well as 94 additional drugs that should be avoided.<\/p>\n<p>The <a href=\"https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir--paxlovid-\/\">NIH<\/a> recommends, before prescribing Paxlovid, healthcare providers should counsel patients on all available <a href=\"https:\/\/www.theepochtimes.com\/t-covid-19-treatment\">COVID-19 treatment<\/a> options and carefully review the patient\u2019s medications, including over-the-counter medications, herbal supplements, and recreational drugs, to evaluate potential drug-drug interactions.<\/p>\n<h2><b>Paxlovid Rebound<\/b><\/h2>\n<p>In the spring, doctors began reporting Paxlovid rebound. According to a <a href=\"https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp\">CDC advisory<\/a>, people who take Paxlovid for COVID-19 could experience a resurgence of the infection between two and eight days after initial recovery and have a recurrence in symptoms and again test positive for the virus.-<\/p>\n<p>The CDC recommends patients experiencing Paxlovid rebound re-isolate for at least five days. There is currently limited information around the Paxlovid rebound although case reports show that most COVID-19 rebound occurrences are mild and there are currently no reports of severe disease.<\/p>\n<p>A big part of the confusion around Paxlovid is the amount of contradictory messaging coming from Pfizer and government agencies.<\/p>\n<p>On Pfizer\u2019s Paxlovid <a href=\"https:\/\/www.paxlovid.com\/\">website<\/a>, there is \u201ctake it at your own risk\u201d-type messaging embedded in their verbiage. For example, they state \u201cthere is limited information about the safety and effectiveness of using Paxlovid to treat people with mild-to-moderate COVID-19.\u201d And yet White House officials are pushing it, <a href=\"https:\/\/www.whitehouse.gov\/briefing-room\/press-briefings\/2022\/04\/26\/press-briefing-by-press-secretary-jen-psaki-and-white-house-covid-19-response-coordinator-dr-ashish-jha\/\">criticizing doctors<\/a> for being too hesitant to prescribe the drug, and most recently <a href=\"https:\/\/www.theepochtimes.com\/us-to-pay-pfizer-2-billion-for-3-7-million-more-courses-of-paxlovid_4922710.html\">purchasing<\/a> more courses of the drug.<\/p>\n<p>The <a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7148e2.htm\">CDC states<\/a> \u201cthere is limited real-world evidence on the benefit of Paxlovid according to vaccination status, age group, and underlying health conditions\u201d but, in the same breath, states that Paxlovid should be prescribed to eligible adults to reduce the risk of COVID-19-associated hospitalization. They support this by pointing to a study using a large electronic health record data set using a Cox proportional hazards model to estimate a 51 percent reduced hospitalization rate. There is still no new randomized double-blind control clinical trial or real-world data to confirm this outcome.<\/p>\n<p><strong>Sources<\/strong><\/p>\n<p><em><a href=\"https:\/\/www.theepochtimes.com\/us-to-pay-pfizer-2-billion-for-3-7-million-more-courses-of-paxlovid_4922710.html\">https:\/\/www.theepochtimes.com\/us-to-pay-pfizer-2-billion-for-3-7-million-more-courses-of-paxlovid_4922710.html<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment\">https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.researchsquare.com\/article\/rs-1705061\/v1\">https:\/\/www.researchsquare.com\/article\/rs-1705061\/v1<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp\">https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2022-04-05\/pfizer-s-5-billion-bill-for-u-s-takes-big-bite-from-covid-aid\">https:\/\/www.bloomberg.com\/news\/articles\/2022-04-05\/pfizer-s-5-billion-bill-for-u-s-takes-big-bite-from-covid-aid<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/s28.q4cdn.com\/781576035\/files\/doc_financials\/2022\/q1\/Q1-2022-Earnings-Charts-FINAL-(1).pdf\">https:\/\/s28.q4cdn.com\/781576035\/files\/doc_financials\/2022\/q1\/Q1-2022-Earnings-Charts-FINAL-(1).pdf<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7125e1.htm\">https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7125e1.htm<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04960202\">https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04960202<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2118542\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2118542<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study\">https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study\">https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.nytimes.com\/2022\/04\/26\/us\/politics\/covid-infections-ashish-jha.html\">https:\/\/www.nytimes.com\/2022\/04\/26\/us\/politics\/covid-infections-ashish-jha.html<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.nytimes.com\/2022\/03\/21\/well\/live\/can-covid-symptoms-rebound-after-taking-paxlovid.html\">https:\/\/www.nytimes.com\/2022\/03\/21\/well\/live\/can-covid-symptoms-rebound-after-taking-paxlovid.html<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.reuters.com\/world\/us\/us-cdc-director-tests-positive-covid-19-again-2022-10-31\/\">https:\/\/www.reuters.com\/world\/us\/us-cdc-director-tests-positive-covid-19-again-2022-10-31\/<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2022\/04\/26\/fact-sheet-biden-administration-increases-access-to-covid-19-treatments-and-boosts-patient-and-provider-awareness\/\">https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2022\/04\/26\/fact-sheet-biden-administration-increases-access-to-covid-19-treatments-and-boosts-patient-and-provider-awareness\/<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.fda.gov\/media\/155051\/download\">https:\/\/www.fda.gov\/media\/155051\/download<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.fda.gov\/media\/155049\/download\">https:\/\/www.fda.gov\/media\/155049\/download<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac443\/6599020\">https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac443\/6599020<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.paxlovid.com\/faq\">https:\/\/www.paxlovid.com\/faq<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/emergency.cdc.gov\/han\/2022\/pdf\/CDC_HAN_467.pdf\">https:\/\/emergency.cdc.gov\/han\/2022\/pdf\/CDC_HAN_467.pdf<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.fda.gov\/media\/155050\/download\">https:\/\/www.fda.gov\/media\/155050\/download<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.fda.gov\/media\/158165\/download\">https:\/\/www.fda.gov\/media\/158165\/download<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp\">https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir--paxlovid-\/\">https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir\u2013paxlovid-\/<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2118542\/suppl_file\/nejmoa2118542_appendix.pdf\">https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa2118542\/suppl_file\/nejmoa2118542_appendix.pdf<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/beta.clinicaltrials.gov\/study\/NCT04960202\">https:\/\/beta.clinicaltrials.gov\/study\/NCT04960202<\/a><\/em><\/p>\n<p><em><a href=\"https:\/\/www.bloomberg.com\/press-releases\/2022-06-14\/pfizer-reports-additional-data-on-paxlovid-supporting-upcoming-new-drug-application-submission-to-u-s-fda\">https:\/\/www.bloomberg.com\/press-releases\/2022-06-14\/pfizer-reports-additional-data-on-paxlovid-supporting-upcoming-new-drug-application-submission-to-u-s-fda<\/a><\/em><\/p>\n<p><em>https:\/\/www.medicaljournals.se\/acta\/download\/10.1080\/00015550310002611\/<\/em><\/p>\n<div class=\"author_wrapper\">\n<div class=\"one_author_block round\">\n<div class=\"top_row\">\n\t\t\t\t\t<a href=\"https:\/\/www.theepochtimes.com\/author-christy-prais\"><img decoding=\"async\" src=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/ChristyPrais_WEB.jpg\" alt=\"Christy Prais\"   style=\"display:none\"><\/a>\n\t\t\t\t\t<\/div>\n<p>Christy A. Prais received her business degree from Florida International University. She is founder and host of Discovering True Health, a YouTube Channel and podcast dedicated to health and wellness, and contributing journalist for the Epoch Times. Christy also serves on the advisory board at the Fostering Care Healing School.  <\/p>\n<\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Biden administration and government agencies continue to push Pfizer\u2019s COVID-19 emergency use authorization product, Paxlovid, even with\u00a0insufficient new trial data showing effectiveness in the current population. Pfizer\u2019s initial clinical trial for Paxlovid in 2021, which earned it an\u00a0emergency use authorization\u00a0(EAU) by the FDA, seemed quite promising. Results showed a relative risk reduction of progression &hellip;<\/p>\n","protected":false},"author":1,"featured_media":1786199,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[547],"tags":[9369,6962,5458,11717,7054,11716,3688,3819,3765],"class_list":["post-1786196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-bongino-report","tag-for","tag-the","tag-bongino","tag-evidence-based","tag-houses","tag-paxlovid","tag-push","tag-report","tag-white"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/1786196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=1786196"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/1786196\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/1786199"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=1786196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=1786196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=1786196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}